|Title||Bacterial Coinfections in Coronavirus Disease 2019.|
|Publication Type||Journal Article|
|Year of Publication||2021|
|Authors||Westblade LF, Simon MS, Satlin MJ|
|Date Published||2021 10|
|Keywords||Anti-Bacterial Agents, Bacteria, Bacterial Infections, Bacterial Physiological Phenomena, Coinfection, COVID-19, Humans, SARS-CoV-2|
Bacterial coinfections increase the severity of respiratory viral infections and were frequent causes of mortality in influenza pandemics but have not been well characterized in patients with coronavirus disease 2019 (COVID-19). The aim of this review was to identify the frequency and microbial etiologies of bacterial coinfections that are present upon admission to the hospital and that occur during hospitalization for COVID-19. We found that bacterial coinfections were present in <4% of patients upon admission and the yield of routine diagnostic tests for pneumonia was low. When bacterial coinfections did occur, Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae were the most common pathogens and atypical bacteria were rare. Although uncommon upon admission, bacterial infections frequently occurred in patients with prolonged hospitalization, and Pseudomonas aeruginosa, Klebsiella spp., and S. aureus were common pathogens. Antibacterial therapy and diagnostic testing for bacterial infections are unnecessary upon admission in most patients hospitalized with COVID-19, but clinicians should be vigilant for nosocomial bacterial infections.
|Alternate Journal||Trends Microbiol|
|PubMed Central ID||PMC8026275|
Lars Westblade, Ph.D.